AlphaStocks
6.0
Consider Buy

ELI LILLY & Co (LLY)

Health Care / Pharmaceuticals

S&P 500

$988.50

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#259out of 1126 in Health Care

Is ELI LILLY & Co a Good Investment in 2026?

ELI LILLY & Co (LLY) scores 6.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates ELI LILLY & Co as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. ELI LILLY & Co currently trades above its estimated fair value of $656, suggesting limited upside at current prices. ELI LILLY & Co ranks #259 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E43.1ROE82.0Market Cap886BDiv Yield0.6

Estimated Fair Value

$656.4851% above

Trading above estimated fair value. P/e of 43x implies high growth expectations. rapid eps growth (96%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Stalwart

Greenblatt

Neutral

Top 25% (rank 19%)

Frequently Asked Questions

Is ELI LILLY & Co (LLY) a good investment?
Based on AlphaStocks' composite analysis, ELI LILLY & Co (LLY) scores 6.0 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading above estimated fair value. P/e of 43x implies high growth expectations. rapid eps growth (96%) partially justifies the premium.
What is ELI LILLY & Co's Piotroski F-Score?
ELI LILLY & Co's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LLY overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $656, LLY appears overvalued. The stock currently trades 51% above its estimated fair value. Trading above estimated fair value. P/e of 43x implies high growth expectations. rapid eps growth (96%) partially justifies the premium.
How does LLY compare to other Health Care stocks?
ELI LILLY & Co ranks #259 out of 1126 stocks in the Health Care sector, placing it in the top 23% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about LLY?
AlphaStocks evaluates LLY using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 6.0/10.

Similar Stocks

FTIPARRAZN

Compare LLY with

LLY vs FTILLY vs PARRLLY vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer